[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100425088":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":58,"collaborators":24,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":24,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":24,"enrollmentInfo":68,"targetDuration":24,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":42,"whyStopped":24,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"National Institutes of Health Clinical Center (CC)","NIH",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental therapy: Dose Escalation","EXPERIMENTAL","Escalating doses of autologous anti-CD22-CAR T-cells in subjects to determine the MTD",[13],"Biological: CD22CART cell infusion",{"label":15,"type":10,"description":16,"interventionNames":17},"Experimental therapy: Dose Expansion","Autologous anti-CD22-CAR T-cells at the MTD",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","CD22CART cell infusion","The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg\u002Fm2\u002Fdose Day -2: cyclophosphamide 900 mg\u002Fm2\u002Fdose Day 0: CD22CART infusion (starting at dose level 1 \\[DL1\\]: 1 x 105 transduced CAR-T cells\u002Fkg) on Day 0 participants will be evaluated for response at Day 28 post-CD22CART infusion.",[9,15],null,[26],{"name":27,"affiliation":28,"role":29},"Robert J Kreitman, M.D.","National Cancer Institute (NCI)","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Olena S Sierra Ortiz","CONTACT","(240) 858-3185","olena.sierraortiz@nih.gov",{"name":27,"role":33,"phone":37,"phoneExt":24,"email":38},"(301) 648-7375","kreitmar@mail.nih.gov",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"National Institutes of Health Clinical Center","RECRUITING","Bethesda","Maryland","20892","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-77.10026,38.98067,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":57,"phoneExt":24,"email":24},"For more information at the NIH Clinical Center contact National Cancer Institute Referral Office","888-624-1937",{"type":59,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100425088","phase-1-phase-i-study-of-anti-cd22-chimeric-receptor-t-cells-in-patients-with-relapsedrefractory-hairy-cell-leukemia-and-variant-100425088",false,"NCT04815356","Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed\u002FRefractory Hairy Cell Leukemia and Variant","* INCLUSION CRITERIA\n* Histologically confirmed diagnosis of HCL or HCLv according to morphological and immunophenotypic criteria of WHO classification \\[WHO, 2008 revised 2016\\] of lymphoid neoplasm.\n* Participants should have any of the following indications for therapy:\n\n  * ANC \\\u003C1\u002FnL,\n  * Hemoglobin \\\u003C10g\u002FdL,\n  * Platelets\\\u003C100\u002FnL,\n  * Symptomatic splenomegaly,\n  * HCL mass with short axis \\> 2 cm outside or \\>0.5 cm inside the CNS,\n  * HCL\u002FHCLv count \\>5\u002FnL in blood or \\>25\u002Fmm\\^3 in CSF,\n  * HCL\u002FHCLv count doubling time \\\u003C6 months and increasing lytic or blastic bone lesions\n\nParticipants who have eligible blood counts within 4 weeks from the initiation of study will not be considered ineligible if subsequent blood counts prior to enrollment fluctuate and become ineligible up until the time of enrollment.\n\n* HCL\u002FHCLv, after prior treatment with, ineligible for, refusal of, or inability to obtain 1)rituximab given concurrently with or sequentially after purine analog, 2) moxetumomab pasudotox-tdft, and 3) BRAF-inhibition.\n* CD22 expression must be detected on greater than 80% of malignant cells by flow cytometry.\n* Participants must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease (MRD) detected by flow cytometry or immunohistochemistry.\n* Age \\>=18 years\n* ECOG performance \\\u003C=2 (Karnofsky \\>=60%, see Appendix A), participants are exempt from this criterion if poor performance status is related to HCL.\n* Participants must have adequate organ function as defined below: Participants must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met. If participants exhibit minor lab abnormalities that are determined to be related to HCL (not therapy-related), then those participants will be allowed to participate\n\n  * Total bilirubin \\\u003C= 3 ULN, unless consistent with Gilbert s (ratio between total and direct bilirubin \\> 5)\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C= 3x upper limit of normal (ULN)\n  * Alkaline phosphatase \\\u003C 2.5 ULN\n  * Serum creatinine \\\u003C= 1.5 mg\u002FdL or creatinine clearance \\>= 60 mL\u002Fmin\u002F1.73 m\\^2 for participants with creatinine levels above institutional normal calculated using eGFR or measured\n  * Serum albumin \\> 2 g\u002FdL\n* Prothrombin time (PT)\u002FInternational Normalized Ratio (INR) \\\u003C 2.5x ULN (if on warfarin, PT\u002FINR \\\u003C 3.5x ULN; If on any other anticoagulation, PT \\\u003C 2.5x ULN\n* Fibrinogen \\>= 0.5x lower limit of normal\n* Participants with CNS disease are eligible, with exceptions\n* Participants with history of allogeneic stem cell transplantation are eligible if at least 100 days post-transplant, if there is no evidence of active graft-versus-host disease (GVHD) and no longer taking immunosuppressive agents for at least 30 days prior to initiation of study intervention.\n* Women of childbearing potential (WOCBP) must agree to use effective contraception (barrier, hormonal, intrauterine device \\[IUD\\], abstinence, surgical sterilization) at the study entry and up to 12 months after the last dose of combined chemotherapy or 4 months after cells infusion, whichever is later.\n\nMen must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) at the study entry and up to 4 months after the last dose of study drug.\n\n* Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 4 months after the last dose of study drug.\n* Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA\n\n* Pregnancy\n* Systemic chemotherapy, immunotherapy, or radiation therapy \\\u003C= 2 weeks prior to apheresis with the following exception:\n\n  * Participants receiving steroids may be enrolled, provided there has been no increase in dose for at least 1 week prior to starting apheresis;\n  * For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment (including CNS radiation), with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the participant has measurable\u002Fevaluable disease outside the radiation port.\n* Other anti-neoplastic investigational agents, or antibody-based therapies currently or within 2 weeks prior to apheresis\n* Participants taking warfarin\n* Prior CAR therapy within 30 days prior to apheresis or prior CAR therapy at any time with evidence for persistence of CAR T cells in blood samples (circulating levels of genetically modified cells of \\>= 5% by flow cytometry)\n* Seropositive for human immunodeficiency virus (HIV) antibody. (Participants with HIV are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy in the future should study results indicate effectiveness.)\n* Seropositive for hepatitis C virus (HCV) or positive for hepatitis B surface antigen (HbsAG). Participants who convert to negative will not be excluded for history of positive test.\n* Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, asthma, chronic obstructive pulmonary disease, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject\n* History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e., gentamicin)","ALL","18 Years",{"count":69,"type":70},27,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","Background:\n\nCAR (Chimeric Antigen Receptor) T cell therapy is a type of cancer treatment in which a person s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells. Researchers want to see if this treatment can help people with hairy cell leukemia (HCL).\n\nObjective:\n\nTo test whether it is safe to give anti-CD22 CAR T cells to people with HCL.\n\nEligibility:\n\nAdults ages 18 and older with HCL (classic or variant type) who have already had, are unable to receive, or have refused other standard treatments for their cancer.\n\nDesign:\n\nParticipants will be screened with the following:\n\nMedical history\n\nPhysical exam\n\nBlood and urine tests\n\nBiopsy sample\n\nElectrocardiogram\n\nEchocardiogram\n\nLung function tests\n\nImaging scans\n\nSome screening tests will be repeated during the study.\n\nParticipants may need to have a catheter placed in a large vein.\n\nParticipants will have magnetic resonance imaging of the brain.\n\nParticipants will have a neurologic evaluation and fill out questionnaires.\n\nParticipants will have leukapheresis. Blood will be removed from the participant. A machine will divide whole blood into red cells, plasma, and lymphocytes. The lymphocytes will be collected. The remaining blood will be returned to the participant.\n\nParticipants will get infusions of chemotherapy drugs.\n\nParticipants will get an infusion of the anti-CD22 CAR T cells. They will stay at the hospital for 14 days. Then they will have visits twice a week for 1 month.\n\nAfter treatment, participants will be followed closely for 6 months, and then less frequently for at least 5 years. Then they will have long-term follow-up for 15 years.",[76,77],"Hairy Cell Leukemia","Hairy Cell Leukemia Variant",[79,80,81],"CD-22 Expressing Tumor","Chimeric Antigen Receptor","Adoptive Immunotherapy","2026-05-02",{"date":84,"type":85},"2026-05-05","ACTUAL",{"date":87,"type":85},"2022-05-23",{"date":89,"type":70},"2036-12-01",{"name":28,"class":6},1]